Laurence Vanlemmens

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 578 citations

5-Year Analysis, Breast Oncology, Oncology +10

Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis

Céline Lefèbvre, Thomas Bachelot, Thomas Filleron et al. · PLoS Medicine · 2016 · 388 citations · Full text

Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort

Élisa Gobbini, Monia Ezzalfani, Véronique Dièras et al. · European Journal of Cancer · 2018 · 274 citations

Prognostic Evaluation, Breast Oncology, Medicine +9

Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer

Carlos H. Barrios, Mei-Ching Liu, Soo Chin Lee et al. · Breast Cancer Research and Treatment · 2010 · 196 citations · Full text

Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008–2016

Élise Deluche, Alison Antoine, Thomas Bachelot et al. · European Journal of Cancer · 2020 · 180 citations

Metastatic Breast Cancer, Breast Oncology, Cancer Epidemiology +9